Cantargia AB (publ) (STO: CANTA)

Market Cap	732.18M
Revenue (ttm)	n/a
Net Income (ttm)	-227.96M
Shares Out	183.69M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,144
Open	3.994
Previous Close	3.934
Day's Range	3.902 - 3.998
52-Week Range	2.564 - 5.200
Beta	1.72
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA

Financial Performance

In 2023, GOMX's revenue was 237.84 million, an increase of 19.89% compared to the previous year's 198.38 million. Losses were -92.60 million, -59.35% less than in 2022.